Eton Pharmaceuticals, Inc. (ETON) Q2 FY26 Earnings Call

Raised guidance, expanding margins, and Hemangiol execution support momentum, while ASN001 remains a later-stage growth catalyst.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-13
Length49 minutes
EPS$0.35
Revenue$37.6M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All ETON earnings ยท Back to ETON overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.